(1)がん治療薬（特にアンメット・メディカル・ニーズの高い腎臓がんや膵臓がんの治療薬）の研究・開発
がん細胞で高発現しているエリスロポエチン受容体の機能解析から新たに発見した「がん細胞の生存・増殖メカニズム」に直接作用する化合物（新規ペプチド及び低分子化合物）を創出し、その有効性と安全性を確認してPOC取得まで手掛けます。POC取得後は、国内外の製薬会社に導出し、医薬品として上市を目指します。
(1) Development of cancer treatment drugs (Focusing on renal and pancreatic cancers which have high unmet medical needs).
Almost all cancer cells are known to express high level of Erythropoietin receptor. Based on a functional analysis of this receptor, we will obtain new chemical entity (peptide and small molecule) which directly impacts viability and growth mechanism of the cancer cell and work to obtain POC including efficacy and safety of the chemical entity. We plan to partner with companies beyond POC in order to provide the chemical entity to patients as treatment drugs.
(2)がん以外の増殖性疾患治療薬の研究・開発
(1)で創出した化合物を用いて種々の増殖性疾患（例えば、糖尿病性網膜症や腺筋症・筋腫等）に対する有効性を動物モデルや臨床検体を用いて検証し、新規疾患への展開を目指します。
(2) Research and development of treatment against proliferative disease other than cancer
By using animal models as well as clinical specimen for the entity found through activity of (1), we will search for other indications such as diabetic retinopathy, endometriosis and/ or myoma.
(3)新規創薬標的の探索を目指した研究
自社及び国内外のアカデミアとの協業により新たな創薬標的を探索し、その標的に作用する化合物を創出し、動物モデルや臨床検体を用いて治療薬としての可能性を検証します。
(3) Research for other novel targets
We will seek for new drug targets in-house as well as through collaboration with academia globally. We will also create and evaluate new compound targeting the new target for potential of use as treatment drug.